Collgard Biopharmaceuticals Featured in This Week's Edition Of IHT World; Program To Air in 96 Countries Beginning With the U.S. Tonight and Asia and the Middle East On Sunday.Business Editors & Health/Medical Writers BIOWIRE2K BOSTON--(BUSINESS WIRE)--Dec. 6, 2002 Please be advised that this week's edition of IHT IHT International Herald Tribune (newspaper) IHT Inheritance Tax (UK) IHT Institution of Highways & Transportation (UK) IHT Intermittent Hypoxic Training World, a co-production of International Herald Tribune International Herald Tribune Daily newspaper published in Paris. It has long been the staple source of English-language news for American expatriates, tourists, and businesspeople in Europe. television and RAINEWS 24, will feature a five-minute story highlighting Collgard Biopharmaceuticals (www.collgard.com), the tissue therapeutics company, and its progress in developing Tempostatin(TM) as an oral agent for the treatment of organ failure, restenosis and cancer. Air locations, times and dates include: -- United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. Tonight, Friday, December 6th on KCSM in San Francisco San Francisco (săn frănsĭs`kō), city (1990 pop. 723,959), coextensive with San Francisco co., W Calif., on the tip of a peninsula between the Pacific Ocean and San Francisco Bay, which are connected by the strait known as the Golden at 7 p.m. -- Asia and Middle East Sunday, December 8th, on Star TV, at 8:30 p.m. (Hong Kong Hong Kong (hŏng kŏng), Mandarin Xianggang, special administrative region of China, formerly a British crown colony (2005 est. pop. 6,899,000), land area 422 sq mi (1,092 sq km), adjacent to Guangdong prov. time), 2:30 p.m. and 9 p.m. (Israel time). For further information and/or a list of additional networks, air times and dates: Marjie@collgard.com; 011-972-55-365-220. About Collgard Biopharmaceuticals Founded in 1996, Collgard Biopharmaceuticals is a clinical stage tissue therapeutics company, led by a global medical and drug team based in Boston, Atlanta and Tel Aviv. The company is currently engaged in phase II clinical studies evaluating a novel approach to the prevention and treatment of organ failure, restenosis and specific cancers. Collgard's scientific and clinical collaborators include the Mayo Clinic, the U.S. National Cancer Institute, and the European Organization for Research and Treatment of Cancer (EORTC EORTC European Organization for Research and Treatment of Cancer ). |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion